NCT03698227终止2 期
Efficacy of Olaratumab and Rechallenge With Doxorubicin in Anthracycline Pretreated, Advanced Soft Tissue Sarcoma Patients. An Exploratory Phase-II Study
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest4 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2018年11月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 4
- 主要终点
- Progression-free survival rate after 3 months (PFSR3), assessed by applying RECIST 1.1
研究概览
简要总结
This is an exploratory, prospective, open label, single arm, phase II-study for the evaluation of efficacy and feasibility (as determined by safety and tolerability) of olaratumab and doxorubicin rechallenge in anthracycline pretreated locally advanced (unresectable) or metastatic soft tissue sarcoma patients.
详细描述
Until now, rechallenge with anthracyclines in patients with metastatic STS which had a benefit from prior anthracycline containing therapy was never investigated in a prospective study.
Due to the very promising effect of olaratumab and doxorubicin in anthracycline-naïve patients and further taking into consideration the results of the retrospective anthracycline rechallenge study, there is a clear rationale to evaluate the effects of olaratumab and doxorubicin also in anthracycline pretreated patients by conducting a prospective clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically confirmed soft tissue sarcoma (STS) Note: Evidence of disease progression at study entry is required.
- •Treated in any order (neoadjuvant, adjuvant or for metastatic disease) with an anthracycline containing chemotherapy (The participant may have had any number of prior systemic cytotoxic therapies for advanced/metastatic disease. All previous anticancer treatments must be completed ≥ 3 weeks (21 days) prior to first dose of study drug.)
- •No progression on prior therapy with anthracyclines or within three months after stopping this therapy
- •Signed written informed consent
- •Men and women aged ≥ 18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Locally advanced (unresectable) or metastatic disease
- •Presence of measurable or non-measurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al. 2009)
- •Adequate haematologic, organ, and coagulation function within 2 weeks (14 days) prior to enrollment:
- •Absolute neutrophil count (ANC) ≥ 1,500/mm3; G-CSF is not permitted within 2 weeks (14 days) prior to enrollment
- •Platelet count ≥ 100,000/mm3
- •Creatinine clearance ≥ 45 mL/min (calculated by using the Cockcroft-Gault formula (refer to study protocol Appendix 4)
- •Total bilirubin ≤ upper limit of normal (ULN). In patients with Gilbert's Syndrome, total bilirubin should be < 3 mg/dL
- •AST/ALT ≤ 3.0 x upper limit of normal (ULN); in case of liver involvement, AST/ALT ≤ 5.0 x are acceptable
- •Haemoglobin ≥ 9 g/dl. If haemoglobin <9 g/dl, blood transfusion is permitted. If haemoglobin cannot be enhanced to ≥ 9 g/dl, patient cannot be included into the study
- •International Normalized Ration (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 x ULN
- •Partial thromboplastin time (PTT or aPTT) ≤ 1.5 x ULN if not on anticoagulant therapy. For patients receiving anticoagulants, coagulation parameters within the intended or expected range for their therapeutic use are allowed. Patients must have no history of active bleeding (defined as within 14 days of first dose of study drug) or pathological condition that carries a high risk of bleeding (for example, tumor involving major vessels or known esophageal varices)
- •If routine urinalysis ≥2+ proteinuria, patient must have ≤1000 mg protein on a 24-hour urine, or urine protein/creatinine ratio ≤1 on spot urine
- •Left ventricular ejection fraction (LVEF) ≥50% assessed within 28 days prior to enrollment
- •Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrollment (refer to study protocol Appendix 3)
- •Females of child-bearing potential and males and must agree to use highly effective contraceptive precautions during the trial and up to 6 months following the last dose of study drug (refer to study protocol Appendix 3)
- •The participant has, in the opinion of the investigator, a life expectancy of at least 3 months
排除标准
- •Diagnosis of GIST or Kaposi sarcoma
- •Active central nervous system (CNS) or leptomeningeal metastasis (brain metastasis) at the time of enrollment. Participants with a history of a CNS metastasis previously treated with curative intent (for example, stereotactic radiation or surgery) that have not progressed on follow-up imaging, have been asymptomatic for at least 60 days and are not receiving systemic corticosteroids and/or anticonvulsants, are eligible. Participants with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before enrollment to rule out brain metastasis
- •Prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation
- •The participant has symptomatic congestive heart failure (CHF), or severe cardiac arrhythmia
- •The participant has unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction within 6 months of enrollment
- •The participant has a QTcB interval calculated using Bazett's formula interval of >450 milliseconds (msec) for males and >470 msec for females on screening electrocardiogram (ECG)
- •Females who are pregnant or breastfeeding
- •Known allergy to any of the treatment components including a history of allergic reactions attributed to compounds of chemical or biological composition similar to olaratumab, dexrazoxane or doxorubicin
- •The participant has a known active fungal, bacterial, or viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required)
- •Known history of active bleeding (defined as within 14 days of first dose of study drug) or pathological condition that carries a high risk of bleeding (for example, tumor involving major vessels or known esophageal varices)
- •History of another primary cancer, with the exception of i) curatively treated non-melanomatous skin cancer or ii) curatively treated cervical carcinoma in situ or iii) other primary non-haematologic malignancies or solid tumor treated with curative intent, no known active disease and no treatment administered during the last 3 years prior to enrollment
- •Electively planned or required major surgery during the course of the clinical trial
- •Any condition that, in the opinion of the investigator, would compromise the well-being of the participant or the study or prevent the participant from meeting or performing study requirements
- •On-treatment participation in another clinical study in the period 30 days prior to start of study treatment and during the study
- •Legal incapacity or limited legal capacity
- •Any condition that requires concomitant vaccination with yellow fever vaccine
研究组 & 干预措施
Study treatment
Experimental
- Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.
- Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles
- Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles
- Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle
干预措施: Olaratumab (Drug)
Study treatment
Experimental
- Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.
- Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles
- Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles
- Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle
干预措施: Dexrazoxane (Drug)
Study treatment
Experimental
- Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.
- Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles
- Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles
- Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle
干预措施: Doxorubicin (Drug)
结局指标
主要结局
Progression-free survival rate after 3 months (PFSR3), assessed by applying RECIST 1.1
时间窗: After 3 months treatment
number of patients proven progression-free and alive after 3 months divided through the total number of patients in the all-treated-subjects population
次要结局
- Progression free survival (PFS)(6 months of Follow Up)
- Overall survival (OS)(6 months of Follow Up)
- Disease control rate (DCR) (i.e. CR, PR or SD)(6 months of Follow Up)
- Objective response rate (ORR) (i.e. CR or PR)(6 months of Follow Up)
- Assessment of adverse events(During study conduct up to a maximum of 18 months (EOT))
- Study therapy discontinuation rate due to cardiac toxicity(After treatment discontinuation up to a maximum of 18 months (EOS))
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Efficacy of Olaratumab and Re-Treatment with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients.locally advanced (unresectable) or metastatic soft tissue sarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001124-20-DEIKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest60
已完成
1 期
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue SarcomaSoft Tissue SarcomaNCT03283696Eli Lilly and Company24
终止
2 期
AMTEC IIT: Phase 2 Multiarm Study in TNBCAnatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaNCT03801369Gordon Mills, MD, PhD24
已完成
1 期
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue SarcomaSoft Tissue SarcomaNCT03126591Eli Lilly and Company41
已完成
2 期
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast CancerBreast CancerNCT00193037SCRI Development Innovations, LLC102